Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.
暂无分享,去创建一个
[1] H. Kitchener,et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial. , 2006 .
[2] A. Howlett,et al. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. , 1999, Advances in experimental medicine and biology.
[3] S. Patil,et al. Human papillomavirus (HPV)-related oropharyngeal nonkeratinizing squamous cell carcinoma: characterization of a distinct phenotype. , 2006, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[4] J. Manola,et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.
[5] A. Bozec,et al. Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts , 2007, British Journal of Cancer.
[6] J. Taube,et al. Inverse Relationship between Human Papillomavirus-16 Infection and Disruptive p53 Gene Mutations in Squamous Cell Carcinoma of the Head and Neck , 2008, Clinical Cancer Research.
[7] W. Hong,et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] David Elashoff,et al. Salivary Transcriptome Diagnostics for Oral Cancer Detection , 2004, Clinical Cancer Research.
[9] J. Califano,et al. Intraoperative molecular margin analysis in head and neck cancer. , 2004, Archives of otolaryngology--head & neck surgery.
[10] A. Venuti,et al. Human papillomavirus therapeutic vaccines in head and neck tumors , 2007, Expert review of anticancer therapy.
[11] Suzanne L Wolden,et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Macková,et al. Prime/boost immunotherapy of HPV16-induced tumors with E7 protein delivered by Bordetella adenylate cyclase and modified vaccinia virus Ankara , 2005, Cancer Immunology, Immunotherapy.
[13] J. Freeman,et al. Diagnosis of nasopharyngeal carcinoma by DNA amplification of tissue obtained by fine-needle aspiration. , 1992, The New England journal of medicine.
[14] J. Baselga,et al. Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225) , 2004, Clinical Cancer Research.
[15] A. Garden,et al. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Jemal,et al. Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.
[17] D. Slaughter,et al. “Field cancerization” in oral stratified squamous epithelium. Clinical implications of multicentric origin , 1953, Cancer.
[18] J. Field,et al. Synchronous oral carcinomas: independent or common clonal origin? , 1998, Cancer research.
[19] R H Hruban,et al. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[20] T. Helliwell,et al. Second primary tumors in patients with head and neck squamous cell carcinoma , 1995, Cancer.
[21] J. Califano,et al. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[22] P. Choyke,et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan , 2007, Nature Medicine.
[23] Ekaterina S. Svistun,et al. Vision enhancement system for detection of oral cavity neoplasia based on autofluorescence , 2004, Head & neck.
[24] K. Shah,et al. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[25] A. Carvalho,et al. Feasibility of quantitative PCR‐based saliva rinse screening of HPV for head and neck cancer , 2005, International journal of cancer.
[26] K. Anastos,et al. Six‐month natural history of oral versus cervical human papillomavirus infection , 2007, International journal of cancer.
[27] R. Zarbo,et al. Common clonal origin of synchronous primary head and neck squamous cell carcinomas: analysis by tumor karyotypes and fluorescence in situ hybridization. , 1995, Human pathology.
[28] D. Sidransky,et al. Phenotypic and genotypic disparity in premalignant lesions: of calm water and crocodiles. , 1998, Journal of the National Cancer Institute.
[29] Tae Woo Kim,et al. Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[30] R H Hruban,et al. Association between cigarette smoking and mutation of the p53 gene in squamous-cell carcinoma of the head and neck. , 1995, The New England journal of medicine.
[31] A. Franchi,et al. Prediction of recurrence by microsatellite analysis in head and neck cancer , 2000, Genes, chromosomes & cancer.
[32] David C. Thomas,et al. Real-Time Gap Ligase Chain Reaction , 2004, Clinical Cancer Research.
[33] D. Sidransky,et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. , 1994, American journal of surgery.
[34] S. Lippman,et al. Predicting cancer development in oral leukoplakia: ten years of translational research. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[35] D. Rimm,et al. Molecular classification identifies a subset of human papillomavirus--associated oropharyngeal cancers with favorable prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] R. Vollmer,et al. Basaloid-squamous carcinoma of the tongue, hypopharynx, and larynx: report of 10 cases. , 1986, Human pathology.
[37] Benjamin D. L. Li,et al. Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer , 1997, Oncogene.
[38] R. Day,et al. Levels of TGF-α and EGFR Protein in Head and Neck Squamous Cell Carcinoma and Patient Survival , 1998 .
[39] J. Epstein,et al. The efficacy of oral lumenoscopy (ViziLite) in visualizing oral mucosal lesions. , 2006, Special care in dentistry : official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry.
[40] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[41] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[42] D. Sidransky,et al. Allelic losses in OraTest-directed biopsies of patients with prior upper aerodigestive tract malignancy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[43] Q. Wei,et al. Epidemiology of carcinogen metabolism genes and risk of squamous cell carcinoma of the head and neck , 2007, Head & neck.
[44] E. Coto,et al. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[45] P. J. Brooks,et al. DNA adducts from acetaldehyde: implications for alcohol-related carcinogenesis. , 2005, Alcohol.
[46] W. Westra,et al. Occult tonsillar carcinoma in the unknown primary , 1998, The Laryngoscope.
[47] C. R. Leemans,et al. Molecular Diagnosis of Surgical Margins and Local Recurrence in Head and Neck Cancer Patients , 2004, Clinical Cancer Research.
[48] W. Westra,et al. Detection of Human Papillomavirus-16 in Fine-Needle Aspirates to Determine Tumor Origin in Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck , 2007, Clinical Cancer Research.
[49] Carole Fakhry,et al. Case-control study of human papillomavirus and oropharyngeal cancer. , 2007, The New England journal of medicine.
[50] Synchronous and metachronous head and neck carcinomas , 1994, Cancer.
[51] M. Maule,et al. Association Between Hypermethylated Tumor and Paired Surgical Margins in Head and Neck Squamous Cell Carcinomas , 2007, Clinical Cancer Research.
[52] Christopher U. Jones,et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] A. Carvalho,et al. Trends in incidence and prognosis for head and neck cancer in the United States: A site‐specific analysis of the SEER database , 2005, International journal of cancer.
[54] J. Walboomers,et al. p53 mutations in relation to human papillomavirus type 16 infection in squamous cell carcinomas of the head and neck , 1997, International journal of cancer.
[55] J. Califano,et al. 11:40 AM: A Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization , 1996 .
[56] Li Zhu,et al. Δ-9-Tetrahydrocannabinol Inhibits Antitumor Immunity by a CB2 Receptor-Mediated, Cytokine-Dependent Pathway1 , 2000, The Journal of Immunology.
[57] K. Shah,et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. , 2004, The Journal of infectious diseases.
[58] J. Grandis,et al. Epidermal growth factor receptor biology in head and neck cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[59] J. Epstein,et al. Increased allelic loss in toluidine blue-positive oral premalignant lesions. , 2003, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.
[60] N D Le,et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[61] J. Califano,et al. Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. , 1996, Cancer research.
[62] A. Olshan,et al. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra. , 1997, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[63] S. Lippman,et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment , 1996, Nature Medicine.
[64] D. Rimm,et al. Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis , 2005, Clinical Cancer Research.
[65] M. Zahurak,et al. Tissue Distribution of Human Papillomavirus 16 DNA Integration in Patients with Tonsillar Carcinoma , 2005, Clinical Cancer Research.
[66] F. Bosch,et al. TP53 DNA contact mutations are selectively associated with allelic loss and have a strong clinical impact in head and neck cancer , 1998, Oncogene.
[67] W. Westra,et al. Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.
[68] H. Dienes,et al. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. , 2003, The American journal of pathology.
[69] L. Turek,et al. Human Papillomavirus in Oral Exfoliated Cells and Risk of Head and Neck Cancer , 2004 .
[70] G. Pond,et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: a Princess Margaret Hospital phase II consortium and National Cancer Institute of Canada Clinical Trials Group Study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] E. Munck‐Wikland,et al. Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer , 2006, International journal of cancer.
[72] C. la Vecchia,et al. Combined effect of tobacco and alcohol on laryngeal cancer risk: a case–control study , 2002, Cancer Causes & Control.
[73] D. Lindquist,et al. The incidence of tonsillar cancer in Sweden is increasing , 2007, Acta oto-laryngologica.
[74] Ruth Katz,et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.
[75] D. Sidransky,et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. , 2000, Journal of the National Cancer Institute.
[76] W. Dinjens,et al. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5–8 , 2003, International journal of cancer.
[77] M. Spitz,et al. Descriptive epidemiology and risk factors for head and neck cancer. , 2004, Seminars in oncology.
[78] A. Cmelak,et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. , 2008, Journal of the National Cancer Institute.
[79] J. Califano,et al. Unknown primary head and neck squamous cell carcinoma: molecular identification of the site of origin. , 1999, Journal of the National Cancer Institute.
[80] M. Hidalgo,et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] K. Ang,et al. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] E. Sturgis,et al. Trends in head and neck cancer incidence in relation to smoking prevalence , 2007, Cancer.
[83] W. Westra,et al. Basaloid Squamous Cell Carcinoma of the Head and Neck is a Mixed Variant That Can be Further Resolved by HPV Status , 2008, The American journal of surgical pathology.
[84] Christopher U. Jones,et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.
[85] S. Franceschi,et al. Human Papillomavirus Types in Head and Neck Squamous Cell Carcinomas Worldwide: A Systematic Review , 2005, Cancer Epidemiology Biomarkers & Prevention.
[86] E. Vokes,et al. Phase II Trial of Gefitinib 250 mg Daily in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck , 2005, Clinical Cancer Research.
[87] H. Morgenstern,et al. Environmental tobacco smoking, mutagen sensitivity, and head and neck squamous cell carcinoma. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[88] J. Jen,et al. Distinguishing second primary tumors from lung metastases in patients with head and neck squamous cell carcinoma. , 1998, Journal of the National Cancer Institute.
[89] A. Schueler,et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[90] Nhu D Le,et al. Toluidine blue staining identifies high-risk primary oral premalignant lesions with poor outcome. , 2005, Cancer research.
[91] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[92] J. Pintos,et al. Effect of smoking cessation and tobacco type on the risk of cancers of the upper aero-digestive tract in Brazil. , 1999, Epidemiology.
[93] Perry Me. The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. , 1994 .
[94] T. Wu,et al. Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. , 2003, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.
[95] Steven S. Chang,et al. Evaluation of Promoter Hypermethylation Detection in Body Fluids as a Screening/Diagnosis Tool for Head and Neck Squamous Cell Carcinoma , 2008, Clinical Cancer Research.
[96] L. Turek,et al. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers , 2004, International journal of cancer.
[97] B. Schmidt,et al. Tongue and tonsil carcinoma , 2005, Cancer.
[98] I. Kawabata,et al. Computerized three-dimensional reconstruction of the crypt system of the palatine tonsil. , 1988, Acta oto-laryngologica. Supplementum.
[99] E. Gabrielson,et al. Multiple head and neck tumors: evidence for a common clonal origin. , 1996, Cancer research.
[100] A. Jemal,et al. Global Cancer Statistics , 2011 .
[101] J. Jen,et al. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. , 2001, Cancer research.
[102] M. Nagarkatti,et al. Δ-9-Tetrahydrocannabinol Enhances Breast Cancer Growth and Metastasis by Suppression of the Antitumor Immune Response1 , 2005, The Journal of Immunology.